Overweight and Obese Adults
Conditions
Brief summary
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
Interventions
DRUGliraglutide monotherapy
liraglutide monotherapy
DRUGliraglutide combined with orlistat
combination therapy
Sponsors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia) * Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up. * No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
Exclusion criteria
* Allergy to liraglutide, orlistat or excipients * Severe liver and kidney dysfunction: ALT or AST\> three times the upper limit of normal, or eGFR \<30 mL/min * Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism * Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers * Pregnant or lactating women * Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight loss | 6 months |
Outcome results
None listed